Kodiak Sciences Inc is is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The most advanced product candidate of the group is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.